Table 2 Estimated number needed to treat according to Trimethoprim/sulfamethoxazole prophylaxis duration
12-months prophylaxis | 6-months prophylaxis | |
|---|---|---|
Rituximab group | ||
PCP events | 2 | 20 |
Non-PCP events | 520 | 502 |
Total subjects | 522 | 522 |
PCP incidence | 0.0038 (0.38%) | 0.0383 (3.83%) |
Absolute risk reduction | 3.45% | |
Relative risk reduction | 90.0% | |
Number needed to treat | 29.0 | |
Non-rituximab group | ||
PCP events | 6 | 18 |
Non-PCP events | 1582 | 1570 |
Total subjects | 1588 | 1588 |
PCP incidence | 0.0038 (0.38%) | 0.0113 (1.13%) |
Absolute risk reduction | 0.75% | |
Relative risk reduction | 66.4% | |
Number needed to treat | 133.3 | |